Get notified when BIAF files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: BIAF bioAffinity Technologies, Inc. 8-K

bioAffinity Technologies reports record CyPath Lung sales, up nearly 300% year-over-year

Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read

Key Changes

  • high

    CyPath Lung diagnostic test achieved record unit sales in April 2026, up nearly 300% compared to April 2025, marking the highest single-month performance for the company's flagship product.

    Item 7.01 view on EDGAR →
  • medium

    Sales figures are preliminary and unaudited, indicating strong commercial momentum but subject to potential revision upon final accounting review.

    8-K: Sales disclosure verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.

Partner

Trade BIAF commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 2:42 PM